Erratum to: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (npj Breast Cancer (2017), 10.1038/s41523-017-0020-z)

Jason J. Zoeller, Roderick T. Bronson, Laura M. Selfors, Gordon B. Mills, Joan S. Brugge

Research output: Contribution to journalComment/debatepeer-review

Abstract

Two references were mistakenly omitted from the first sentence of the introduction. Original text: Extracellular matrix (ECM) proteins produced by diverse tumor types protect tumor cells from death in response to various agents.1,2,3,4 1. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662–668 (1999). 2. Sherman-Baust, C. A. et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377–386 (2003). 3. Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. & Gladson, C. L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin. Cancer Res. 5, 1587–1594 (1999). 4. Pupa, S. M. et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 67, 4271–4277 (2007). Corrected text: Extracellular matrix (ECM) proteins produced by diverse tumor types protect tumor cells from death in response to various agents.1,2,3,4,5,6 1. Muranen, T. et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21, 227–239 (2012). 2. Behbod, F. et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 11, R66 (2009). 3. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662–668 (1999). 4. Sherman-Baust, C. A. et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377–386 (2003). 5. Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. & Gladson, C. L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin. Cancer Res. 5, 1587–1594 (1999). 6. Pupa, S. M. et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 67, 4271–4277 (2007). All subsequent references have been renumbered accordingly. These errors have now been corrected in the HTML and PDF versions of this article.

Original languageEnglish (US)
Article number38
Journalnpj Breast Cancer
Volume3
Issue number1
DOIs
StatePublished - 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Erratum to: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (npj Breast Cancer (2017), 10.1038/s41523-017-0020-z)'. Together they form a unique fingerprint.

Cite this